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AnticancerAbstract A series of new 5a-cholestano [5,6-b] benzothiazines (4–6) has been synthesized by the
reaction of 5a-cholestan-6-one (1–3) with 2-aminothiophenol in the presence of iodine. The struc-
tures of newly synthesized compounds have been established on the basis of spectral and analytical
data. Compounds (1–6) were screened for in vitro anticancer activity against the human cancer cell
lines; SW480 (colon adenocarcinoma cells), A549 (lung carcinoma cells), HepG2 (hepatic carci-
noma cells) and HeLa (cervical cancer cells) using MTT assay during which the products (4–6)
showed marked increase in anticancer activity and in particular, compound 6 showed
IC50 = 13.73 lmol L
1 against HeLa cells, being more effective than Doxorubicin against the same
cells. Compounds 4 and 6 also showed minimum IC50 of 15.83 lmol L
1 and 16.89 lmol L1
against HepG2 and A549 cells, respectively. Compounds (1–6) were also tested for in vitro antimi-
crobial activity against different bacterial as well as fungal strains during which newly synthesized
compounds (4–6) were found more potent than starting compounds (1–3). Compound 4 was found
to be more potent than the reference drug, Chloramphenicol, in the case of Escherichia coli while
compound 5 was found almost equally potential antifungal agent against P. marneffei in compar-
ison with the reference drug, Nystatin.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Steroids have been the important focus of research throughout
the scientiﬁc history. But the recent past has seen an exhaustive
focus of research being diverted towards these biologically
important molecules. This is pertinently true of the rational
semi-synthetic modiﬁcations of steroidal molecules. Probably,
it is because of the various advantages associated with steroid
based chemotherapeutics. These compounds turn out to be
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highly bioavailable because of being capable of penetrating the
cell wall (Bandey et al., 2011). Although various modiﬁcations
of steroids including derivatization cyclization, heterocycliza-
tion etc. have been tried but as far the literature precedents
are concerned, little efforts have been made towards the efﬁ-
cient synthesis and simultaneous biological analysis of steroid
based benzothiazines.
Steroid based antimicrobial agents continue to play a
prominent role in those organisms which do not rely upon
external supply of drugs to ﬁght against pathogens (Savage,
2002) because the entire morbidity and mortality mostly in
developing countries is due to these microbial infections (Qadri
et al., 2005) among which Escherichia coli is responsible for the
most common and serious infectious diseases like invasive dys-
entery and diarrhoea (Zhang et al., 2006). The different mi-
crobes such as Staphylococcus aureus, Streptococcus pyogenes
and Salmonella typhimurium have important effect on the hu-
man’s mucosal health. The infection with these microorgan-
isms may have a signiﬁcant impact on huge demolition of
host tissue and severe diseases (Puerto et al., 2006; Nolan
et al., 1979).
Nitrogen containing steroids have the ability to regulate a
variety of biological processes and thus are potential drug can-
didates for the treatment of a large number of diseases includ-
ing breast cancer (Visvanathan and Davidson, 2003), prostate
cancer (Li et al., 1995), leukaemia (He and Jiang, 1999), auto-
immune diseases (Latham et al., 2003) and osteoporosis (Hos-
king et al., 1998). So is the case with the nitrogen containing
derivative, benzothiazines in which the presence of a fold along
the nitrogen–sulphur axis is one of the features responsible to
impart their biological activity (Gupta et al., 1993; Gautam
et al., 2009; Khandelwal et al., 2013), hence they show broad
spectrum of biological activities such as antagonists (Watana-
be et al., 1996), anticancer (Niewiadomy et al., 2011; Srivastav
et al., 2000; Gupta et al., 1993), vasorelaxant (Cecchetti et al.,
2003), antidiabetic (Matsui et al., 1994), antihypertensive (Kaj-
ino et al., 1991) and antimicrobial (Rathore and Kumar, 2006).
Intrigued by the above observations and in continuation of our
previous work (Shamsuzzaman et al., 2013) herein we repre-
sent one-pot synthesis of steroidal benzothiazines and investi-
gate their antimicrobial as well as anticancer behaviour.2. Experimental
2.1. General remarks
Chemicals were purchased from Merck and Sigma–Aldrich as
‘synthesis grade’ and used without further puriﬁcation. Melt-
ing points were determined on a Koﬂer apparatus and are
uncorrected. The IR spectra were recorded on KBr pellets with
Pye Unicam SP3–100 spectrophotometer and values are given
in cm1. 1H and 13C NMR spectra were run in CDCl3 on a
JEOL Eclipse (400 MHz) instrument with TMS as internal
standard and values are given in ppm (d). Mass spectra were
recorded on a JEOL SX 102/DA-6000 Mass Spectrometer.
Thin layer chromatography (TLC) plates were coated with sil-
ica gel G and exposed to iodine vapours to check the homoge-
neity as well as the progress of reaction. Sodium sulphate
(anhydrous) was used as a drying agent.2.2. Chemistry
2.2.1. General method for the synthesis of steroidal
benzothiazines (4–6)
To a solution of steroidal ketones (1–3) (1 mmol) in absolute
ethanol (10 mL) was added 2-aminothiophenol (1 mmol) and
iodine (2 mmol) in the same solvent (25 mL) and the reaction
mixture was reﬂuxed for about 19–21 h. The progress of the
reaction was monitored by TLC (Petroleum benzene: ether,
3:1). After completion of reaction the excess solvent was re-
moved to three fourths of the original volume under reduced
pressure. Then it was cooled to room temperature, diluted with
Na2S2O7 solution and subsequently with water. The mixture
was extracted in ether, washed with water and ﬁnally dried
over anhydrous Na2SO4. Evaporation of solvents and recrys-
tallization from methanol afforded respective products (4–6).
2.2.1.1. 3b-Acetoxy 5a-cholestano [5,6-b] benzothiazine (4).
Yield: 80%; Solid; m p: 163–165 C; Anal. Calcd. for
C35H51NO2S: C 76.17, H 9.08, N 2.32; Found C 76.45, H
9.35, N 2.55. IR (KBr, cm1): 1714 (OCOCH3), 1650
(C‚N), 3060, 1603 (aromatic), 750 (C–S), 1388 (C–N), 1206
(C–O). 1H NMR (400 MHz, CDCl3): d 6.33–6.28 (m, 4H, aro-
matic), 4.7 (m, 1H, C3 a-H, W½= 15 Hz), 2.03 (s, 3H,
OCOCH3), 1.8 (d, 2H, C4–H2, J = 8.0 Hz), 1.9 (d, 2H, C7–
H2, J = 5.2 Hz), 1.18 (s, 3H, C10–CH3), 0.70 (s, 3H, C13–
CH3), 0.97 & 0.83 (other methyl protons).
13C NMR
(100 MHz, CDCl3): d 174, 163, 148, 129, 128, 126, 124, 122,
73, 48, 46, 42, 39, 35, 26, 24, 22, 20, 17. ESI MS: 549 [M+].
2.2.1.2. 3b-Chloro 5a-cholestano [5,6-b] benzothiazine (5).
Yield: 85%; Solid; m p: 146–147 C; Anal. Calcd. for
C33H48ClNS: C 75.07, H 9.03, N 2.61; Found C 75.32, H
9.19, N 2.66. IR (KBr, cm1): 1626 (C‚N), 3058, 1598 (aro-
matic), 710 (C–S), 1380 (C–N), 740 (C–Cl). 1H NMR
(400 MHz, CDCl3): d 6.43–6.24 (m, 4H, aromatic), 3.5 (m,
1H, C3 a-H, W½= 17 Hz), 2.07 (d, 2H, C7–H2,
J = 8.0 Hz), 1.87 (d, 2H, C4–H2 J = 4.8 Hz), 1.18 (s, 2H,
C10–CH3), 0.75 (s, 3H, C13–CH3), 0.97 & 0.80 (other methyl
protons). 13C NMR (100 MHz, CDCl3): d 164, 146, 127, 126,
125, 123,122, 59, 48, 46, 42, 39, 35, 26, 24, 22, 20, 17. ESI
MS: 525/527 [M+].
2.2.1.3. 5a-Cholestano [5,6-b] benzothiazine (6). Yield: 83%;
Solid; m p: 152–154 C; Anal. Calcd. for C33H48NS: C 80.12,
H 9.86 N 2.63 Found C 80.59, H 10.04, N 2.85. IR (KBr,
cm1): 1628 (C‚N), 3062, 1600 (aromatic), 711 (C–S), 1385
(C–N). 1H NMR (400 MHz, CDCl3): d 6.43, 6.24 (m, 4H, aro-
matic), 2.05 (d, 2H, C4–H2, J = 8.0 Hz), 2.04 (d, 2H, C7–H2,
J = 4.4 Hz), 1.17 (s, 2H, C10–CH3), 0.75 (s, 3H, C13–CH3),
0.97 & 0.80 (other methyl protons). 13C NMR (100 MHz,
CDCl3): d 163, 149, 125, 124, 122.8, 122, 120, 48, 46, 42, 39,
35, 26, 24, 22, 20, 17. ESI MS: 491 [M+].
2.3. Anticancer activity
2.3.1. Cell lines and culture conditions
Human cancer cell lines SW480 (colon adenocarcinoma cells),
HeLa (cervical cancer cells), A549 (lung carcinoma cells), and
HepG2 (hepatic carcinoma cells) were taken for the study.
SW480, A549 and HepG2 cells were grown in RPMI 1640
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um (FBS), 10U penicillin and 100 lg/mL streptomycin at
37 C with 5% CO2 in a humidiﬁed atmosphere. HeLa cells
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(Shaﬁ et al., 2009) supplanted with FCS and antibiotics as de-
scribed above for RPMI 1640. MCF10A immortalized breast
cells were maintained in mammary epithelial basal medium
supplemented with an MEGM mammary epithelial singlequot
kit (Cambrex). NL-20 (normal lung cells), HPC (normal pulp
cells), and HPLF (periodontal ligament ﬁbroblasts) were
grown at 37 C with 5% CO2, 95% air under the humidiﬁed
conditions. Fresh medium was given every second day and
on the day before the experiments were done. Cells were pas-
saged at preconﬂuent densities, using a solution containing
0.05% trypsin and 0.5 mM EDTA.
2.3.2. Cell viability assay (MTT)
The anticancer activity in vitro was measured using the MTT
assay. The assay was carried out according to known protocol
(Berenyi et al., 2013; Wang et al., 2012; Das et al., 2012; Mos-
mann, 1983). Exponentially growing cells were harvested and
plated in 96-well plates at a concentration of 1 · 104 cells/well.
After 24 h incubation at 37 C under a humidiﬁed 5% CO2 to
allow cell attachment, the cells in the wells were respectively
treated with target compounds at various concentrations for
48 h. The concentration of DMSO was always kept below
1.25%, which was found to be non-toxic to the cells. A solu-
tion of 3-(4,5-dimethylthizao1–2-y1)-2,5-diphenyltetrazolium
bromide (MTT), was prepared at 5 mg/mL in phosphate buf-
fered saline (PBS; 1.5 mM KH2PO4, 6.5 mM Na2HPO4,
137 mM NaCl, 2.7 mM KCl; pH 7.4). 20 lL of this solution
was added to each well. After incubation for 4 h at 37 C in
a humidiﬁed incubator with 5% CO2, the medium/MTT mix-
tures were removed and the formazan crystals formed by the
mitochondrial dehydrogenase activity of vital cells were dis-
solved in 100 lL of DMSO per well. The absorbance of the
wells was read with a microplate reader (Bio-Rad Instruments)
at 570 nm. Effects of the drug cell viability were calculated
using cells treated with DMSO as control.
2.3.3. Data analysis
Cell survival was calculated using the formula: Survival
(%) = [(absorbance of treated cells  absorbance of culture
medium)/(absorbance of untreated cells  absorbance of cul-
ture medium)] · 100 (Hui et al., 2012; Liu et al., 2010; Saxena
et al., 2007; Woerdenbag et al., 1993). The experiment was
done in triplicate and the inhibitory concentration (IC) values
were calculated from a dose response curve. IC50 is the concen-
tration in ‘lM’ required for 50% inhibition of cell growth as
compared to that of control. IC50 values were determined from
the linear portion of the curve by calculating the concentration
of agent that reduced absorbance in treated cells, compared to
control cells, by 50%. Evaluation is based on mean values
from three independent experiments, each comprising at least
six microcultures per concentration level.
2.4. In vitro antibacterial activity
Steroidal benzothiazines (4–6) and the steroidal ketones (1–3)
were screened for the in vitro antibacterial activity against the
cultures of S. pyogenes (ATCC 19615), S. aureus (ATCC-25923), P. aeruginosa (ATCC-27853) and E. coli (ATCC-
25922) by disc diffusion method (Cruickshank et al., 1975; Col-
lins, 1976). Standard inoculums 1 · 107  2 · 107 c.f.u. mL1
(0.5 McFarland standards) were introduced onto the surface
of sterile agar plates and a sterile glass spreader was used for
even distribution of the inoculums. The discs measuring 6 mm
in diameter were prepared from Whatman No. 1 ﬁlter paper
and sterilized by dry heat for 1 h at 140 C. The sterile discs pre-
viously soaked in a known concentration of the test compounds
were placed in nutrient agar medium. Solvent and growth con-
trols were also kept. Chloramphenicol was used as a positive
control while the disc poured in DMSO was used as a negative
control. The plates were inverted and incubated at 37 C for
24 h. The susceptibility was assessed on the basis of diameter
of zone of inhibition against different strains of bacteria. Inhibi-
tion zones were measured and compared with standard drug.
Minimum inhibitory concentration (MIC) which is deﬁned
as the lowest concentration of an antibacterial drug that will in-
hibit the visible growth of a micro-organism after overnight
incubation was determined by broth dilution technique. The
nutrient broth which contained logarithmic serially two fold di-
luted amount of test compound and controls were inoculated
with approximately 5 · 105 c.f.u. ml1 of actively dividing bac-
terial cells. The cultures were incubated at 37 C for 24 h and
the growth was monitored visually and spectrophotometrically.
2.5. In vitro antifungal activity
Antifungal screening of steroidal benzothiazines (4–6) and the
steroidal ketones (1–3) was done against the cultures of Can-
dida albicans (ATCC 10231), Aspergillus fumigatus (ATCC
1022), Trichophyton mentagrophytes (ATCC 9533) and Pencil-
lium marneffei (recultured) in DMSO by agar diffusion method
(Khan, 1997; Verma et al., 1998). Sabouraud agar medium was
prepared by dissolving peptone (1 g), D-glucose (4 g) and agar
(2 g) in distilled water (100 mL) and adjusting pH to 5.7. Nor-
mal saline was used to make a suspension of spore of fungal
strain for lawning. A loopful of particular fungal strain was
transferred to 3 mL saline to get a suspension of corresponding
species. 20 mL of agar media was poured into each petri dish.
Excess of suspension was decanted and the plates were dried
by placing in an incubator at 37 C for 1 h. using an agar
punch, wells were made and each well was labelled. A control
was also prepared in triplicate and maintained at 37 C for 3–
4 days.
Minimum inhibitory concentration (MIC) was determined
by broth dilution technique as in antibacterial activity. The
Inhibition zones of compounds (1–6) were compared with Nys-
tatin used as standard drug. The nutrient broth which con-
tained logarithmic serially two fold diluted amount of test
compound and controls was inoculated with approximately
1.6 · 104–6 · 104 c.f.u. mL1. The cultures were incubated at
35 C for 48 h and the growth was monitored.
3. Results and discussion
3.1. Chemistry
3b-Acetoxy-5a-cholestan-6-one 1, 3b-chloro-5a-cholestan-6-
one 2, and 5a-cholestan-6-one 3 were prepared according to
the literature procedure (Anagnostopoulos and Fieser, 1954;
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benzothiazines (4–6) were conventionally synthesized by react-
ing 5a-cholest-6-one (1–3) with iodine and 2-aminothiophenol
in absolute ethanol. The remarkable feature of the reaction is
the formation of 5a-iodoketone in situ as an intermediate
which might be obtained separately by the reaction of ketones
with iodine (Khan et al., 2008). The advantages of this synthe-
sis are to evade the cumbersome 5a-iodocholest-6-ones as
starting materials and to obtain products in better yields. In
spite of this modiﬁcation, the method still remains cumber-
some (19–21 h reﬂux), but still these types of multi component
reactions have proven to be the practical way for achieving
large functionalized molecules because these reactions gener-
ally are one-pot and afford better yields.
The tentative mechanism (Scheme 2) has been proposed for
the formation of steroidal benzothiazines (4–6) from steroidal
ketones (1–3) which involves the formation of 5a-iodo cholest-
6-one in situ as an intermediate, which on further reaction with
2-aminothiophenol undergo SN1 reaction at C5 and condensa-
tion at C6 resulting in cyclization that leads to the formation of
corresponding product. (See Scheme 1).
The selected diagnostic bands of IR spectra of synthesized
products provide useful information for determining struc-
tures of the benzothiazine derivatives. All compounds (4–6)
exhibited absorption bands at 1626–1650 cm1 due to C‚N
stretching and 710–750 cm1 due to C–S. The absorption
band at 3058–3062 cm1 and 1598–1603 cm1 as ascribed to
the aromatic ring also conﬁrmed the formation of benzothia-
zines. The formation of steroidal benzothiazines (4–6) was
further conﬁrmed with the NMR spectra. Assignments of
the signals are based on the chemical shift and intensity pat-
tern. In 1H NMR spectra the multiplet at d 6.43–6.24 shows
the presence of aromatic protons. The singlets appeared at d
1.18 and 0.70 are ascribed to three protons of the methyl
group attached to ‘C10’ and three protons of the methyl
group attached to ‘C13’ respectively.
13C NMR signals are
in good agreement with proposed structures of synthesized
compounds. The compounds exhibited signals at d 163–164
(C6), 48 (C5) while the signals obtained at d 120–149 conﬁrm
the presence of aromatic ring. The distinctive signals were ob-
served in the mass spectra of compounds (4–6) which fol-











Scheme 1 Showing the formationpeaks (M+) for compounds (4–6) were observed at m/z
549, 525/527 and 491, respectively.
3.2. In vitro anticancer activity
Compounds (1–6) were screened for in vitro anticancer activity
against different human cancer cells; SW480, HeLa, A549 and
HepG2. The anticancer activity in vitro was measured using
theMTTassay during which the conversion of soluble yellowish
MTT into the insoluble purple formazan by active mitochon-
drial lactate dehydrogenase of living cells has been used to devel-
op an assay system for measurement of the cell proliferation.
The anticancer screening data reported in Table 1 suggest that
compounds (4–6) showed different levels of cytotoxicity during
which compound 6 showed effective IC50 = 13.73 lmol L
1
against HeLa cell line. Compounds 4 and 6 also showed mini-
mum IC50 value in the range of 15.83 lmol L
1 (HepG2) and
16.89 lmol L1 (A549), respectively. Next to these, compound
4 showed minimum IC50 = 22.67 lmol L
1 against SW480 cell
line. The IC50 shown by the starting compounds (1–3) were
found eitherP40 ormuchhigher>50 lmol L1. It is clear from
the anticancer screening data that after the appending of beno-
thiazine moiety to the steroidal ketone derivatives (1–3), there
occurs moderate to good increase in anticancer activity (Ta-
ble 1). During anticancer screening, none of the compounds
were found as effective as the standard anticancer drugs like
Doxorubicin, 5-Fluorouracil or Cisplatin, except compound 6
which showed IC50 = 13.73 lmol L
1 which is more effective
than 5-Fluorouracil (IC50 = 16.32 lmol L
1) against HeLa cell
line. But further modiﬁcations and derivatization may lead to
the development of more active cytotoxic agents.
To conﬁrm the cytotoxicity of steroidal benzothiazines, com-
pounds (4–6) were tested with some non-cancer cell lines
MCF10A (breast), NL-20 (lung), HPC (pulp) and HPLF (Peri-
odontal) during which none of the synthesized compounds were
found toxic, all the compounds showed GI50 > 55 lmol L
1.
This also suggests that the steroidal benzothiazine derivatives
can be used speciﬁcally for the treatment of cancer cells without
showing toxicity to the non-cancer cells. The GI50 which is the
molar concentration causing 50%growth inhibition of non-can-
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Scheme 2 Mechanism for the formation of steroidal benzothiazines 4–6.
Table 1 Showing anticancer activity data of compounds 1–6
against human cancer cell lines.
Compound IC50 (lmol L
1)a
SW480 A549 HepG2 HeLa
1 39.77 46.13 >50 >50
2 >50 >50 49.22 >50
3 47.28 40.61 >50 >50
4 22.67 29.85 15.83 31.43
5 >50 41.52 37.65 49.18
6 27.73 16.89 >50 13.73
Doxorubicin 10.9 13.5 11.52 12.52
5-Fu 15.71 12.8 33.6 16.32
Cisplatin 3.52 12.1 9.63 9.43
Cell growth inhibition was analysed by the MTT assay.
5-Fu= 5-Fluorouracil.
a IC50 = the concentration of compound that inhibits 50% of cell
growth.
Table 2 The GI50 values shown by compounds 4–6, Doxo-
rubicin, Cisplatin and 5-Fluorouracil against noncancer cells.
Compounds GI50 (lML
1)
Breast Lung Pulp Periodontal
MCF10A NL-20 HPC HPLF
4 68.41 90.21 63.31 >100
5 72.11 >100 59.16 66.33
6 >100 60.92 67.78 >100
Doxorubicin >100 91.77 >100 >100
Cisplatin 26.17 51.25 63.35 61.17
5-FU >100 83.54 73.62 >100
GI50 is the molar concentration causing 50% growth inhibition of
non-cancerous cells.
Values are the mean of triplicates of at least two independent
experiments.
5-FU= 5-Fluorouracil.
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The antimicrobial screening data obtained after treating differ-
ent microbial strains with test doses of the steroidal derivatives
(1–6) are given in Tables 3–6 and the values are reported in
terms of the zone of inhibition in ‘mm’ and minimum inhibi-
tory concentration in ‘lg mL1’. It is clear from the antimicro-
bial screening data that compounds (4–6) showed moderate to
good increase in antimicrobial activity than the starting com-
pounds (1–3). In antibacterial activity, compounds 4 and 6
showed potential inhibition zones against E. coli strain. Even
compound 4 was found to be more potent than the reference
drug, Chloramphenicol, in the case of E. coli strain. As shown
in Table 3, compound 4 showed potential zones of inhibitioni.e. 18.6, 19.6 and 21.5 mm against S. aureus, S. pyogenes
and P. aeruginosa, respectively in comparison with Chloram-
phenicol. Compound 6 also showed inﬂuential zone of inhibi-
tion i.e. 19.4 mm against the E. coli strain which is almost
equal to the inhibition zone of Chloramphenicol i.e. 20.0 mm
against the same strain. The MIC’s of compounds 1–6 with dif-
ferent bacterial strains are given in Table 4 and it is clear from
the data that MIC’s of steroidal ketones (1–3) are two to four
fold higher than those of benothiazine derivatives (4–6) sug-
gesting that compounds (4–6) are active at lower concentra-
tions than those of compounds (1–3). From Table 4 it is also
clear that the lowest concentration at which compound 4
inhibited the visible growth of bacteria is 32 lg/mL and
64 lg/mL while compounds 5 and 6 inhibited the growth of
bacteria at 32 lg/mL, 64 lg/mL and 128 lg/mL against the
Table 3 Showing the zone of inhibition of compounds 1–6 with different bacterial strains.
Compounds
Zone of inhibition (mm)
S. aureus S. pyogenes P. aeruginosa E. coli
1 14.3 ± 0.4 12.2 ± 0.4 12.6 ± 0.2 14.2 ± 0.4
2 12.2 ± 0.2 10.3 ± 0.2 10.4 ± 0.4 11.2 ± 0.2
3 12.5 ± 0.4 11.6 ± 0.5 10.5 ± 0.5 10.2 ± 0.5
4 18.6 ± 0.2 19.6 ± 0.4 21.5 ± 0.5 23.2 ± 0.2
5 19.5 ± 0.4 15.3 ± 0.8 18.2 ± 0.4 15.6 ± 0.6
6 18.6 ± 0.1 15.1 ± 0.6 18.8 ± 0.4 19.4 ± 0.6
Chloramphenicol 21.6 ± 0.5 22.5 ± 0.4 25.2 ± 0.8 20.0 ± 0.2
DMSO – – – –
Table 4 Showing the MIC’s of compounds 1–6 with different
bacterial strains.
Strains MIC (lg/ml)
1 2 3 4 5 6 Chloramphenicol
S. aureus 64 128 256 32 32 32 32
S. pyogenes 64 128 256 32 64 64 32
P. aeruginosa 128 128 128 64 64 128 32
E. coli 64 256 128 32 128 32 32
466 Shamsuzzaman et al.different bacterial strains. From Tables 3 and 4, it is clear that
the compounds which show lower MIC are having larger zone
of inhibition and are therefore active antibacterial agents.
It is clear also from the antifungal screening data that com-
pounds (4–6) showed moderate to good increase in antifungal
activity than the starting compounds (1–3). In antifungal activ-
ity, compounds 4 and 5 showed potential inhibition zones
against P. marneffei strain. But the inhibition zone of com-
pound 5 is larger than compound 4 against P. marneffei in
comparison with the standard drug, Nystatin. As shown inTable 5 Showing the zone of inhibition of compounds 1–6 with di
Compounds Zone of inhibition (mm)
C. albicans T. mentagro
1 13.1 ± 0.5 14.1 ± 0.5
2 12.2 ± 0.2 09.2 ± 0.2
3 14.2 ± 0.5 11.2 ± 0.4
4 24.5 ± 0.3 21.4 ± 0.6
5 19.1 ± 0.4 18.2 ± 0.4
6 23.5 ± 0.2 24.2 ± 0.5
Nystatin 29.0 ± 0.5 29.0 ± 0.5
DMSO – –
Table 6 Showing the MIC’s of compounds 1–6 with different fung
Strains MIC (lg/ml)
1 2 3
C. albicans 256 256 128
T. mentagrophytes 128 256 256
P. marneﬀei 256 128 128
A. fumigatus 128 256 256Table 5, compound 4 showed potential zones of inhibition
i.e. 24.5, 21.4, 16.6 and 15.1 mm against C. albicans, T. ment-
agrophytes, P. marneffei and A. fumigatus, respectively in com-
parison with the reference drug, Nystatin. Compounds 5 and 6
also showed inﬂuential zone of inhibition i.e. 17.4 and 24.2 mm
against the P. marneffei and T. mentagrophytes strains which
are very close to that of Nystatin i.e. 19.5 and 29.0 mm, respec-
tively. The MIC’s of compounds (1–6) with different fungal
strains are given in Table 6 and it is clear from the data that
MIC’s of steroidal ketones (1–3) are two to four fold higher
than those of benothiazine derivatives (4–6) revealing that
compounds (4–6) are active against different fungal strains at
lower concentrations than those of compounds (1–3). From
Table 6 it is also clear that the lowest concentration at which
compounds 4 and 5 inhibited the visible growth of fungi is
32 lg/mL and 64 lg/mL while compound 6 inhibited the
growth of fungi at lower concentration i.e. 32 lg/mL against
the different fungal strains. From the data given in Tables 5
and 6, it is quite clear that the compounds which are showing
lower MIC are having efﬁcacious zone of inhibition and are
therefore active antifungal agent while the compounds which
are not showing lower MIC did not show potential zone offferent fungal strains.
phytes P. marneﬀei A. fumigatus
11.3 ± 0.5 11.5 ± 0.2
10.1 ± 0.5 09.2 ± 0.4
12.1 ± 0.2 10.1 ± 0.3
16.6 ± 0.3 15.1 ± 0.4
17.4 ± 0.5 14.4 ± 0.2
15.8 ± 0.2 16.0 ± 0.5
19.5 ± 0.5 19.5 ± 0.5
– –
al strains.
4 5 6 Nystatin
32 64 32 32
64 64 32 32
32 32 32 32
32 32 32 32
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strains. This study also supports that benzothiazine moiety
after being attached with steroid nucleus might be one of the
factors responsible for enhanced antimicrobial behaviour.
4. Conclusions
In summary, the successfully developed, convenient and oper-
ationally simple reaction for an efﬁcient synthesis of steroidal
benzothiazines involved the reaction of steroidal ketone with
iodine and 2-aminothiophenol in absolute ethanol. The reac-
tion completed in 19–21 h and on completion, better yields
(80–85%) were obtained. This strategy offered a very straight
forward, one-pot and efﬁcient method for access to steroidal
benzothiazines. The anticancer screening data suggest that
compounds (4–6) showed potential increase in anticancer
activity than the starting compounds (1–3) and the possible
reason may be the adjoining of the benzothiazine moiety to
the steroidal nucleus because the presence of fold along the
nitrogen and sulphur axis in benzothiazine derivatives is one
of the features responsible for imparting the biological activity
(Bandyopadhyay et al., 2012; Niewiadomy et al., 2011). Com-
pounds 4 and 6 showed potential anticancer activity with
IC50 = 13.73 lmol L
1 (HeLa) and 15.83 lmol L1 (HepG2),
respectively. None of the compounds showed anticancer activ-
ity equivalent to the standard drugs except compound 4 which
showed more effective anticancer activity than Doxorubicin
against HeLa cells. Thus during anticancer screening com-
pounds 4 and 6 were found to be potential anticancer agents
among all the screened compounds (1–6). All the newly synthe-
sized compounds were found almost non-toxic to the normal
cells which specify that these compounds can be used safely
for the treatment of cancer without damaging the normal cells.
During the antimicrobial screening, all the newly synthesized
compounds (4–6) were found more active than the starting
compounds (1–3). Compound 4 showed potential behaviour
against E. coli (being more active than the reference drug, Cip-
roﬂoxacin) in antibacterial activity while the compound 5 was
found almost equally potent than the reference drug, Nystatin
in the case of P. marneffei strain in antifungal activity. The rea-
son for this increase in the antimicrobial activity in the synthe-
sized compounds (4–6) may be due to the presence of aromatic
functionality present in the product molecule because most of
the heterocyclic compounds adjoined with the aromatic group,
often show potential antimicrobial activity (Bandey et al.,
2011; El-Nakkady et al., 2012). In conclusion, the present
study showed that these one pot synthesized compounds can
be used as a template for future development through modiﬁ-
cation and derivatization to design more potent and selective
anticancer as well as antimicrobial agents.Acknowledgements
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